From Bars to Briefs: Drake vs. Kendrick Meets the Courts

By: Joseph Valcazar

The rap industry is no stranger to a diss track. Whether it was the rap battles of Tupac v. Notorious B.I.G., Nas v. Jay-Z, N.W.A. v. Ice Cube, or Eminem v. Ja Rule, music has been and continues to be a medium for artists to express their opinion of others in the industry. Typically, this bad blood stays within the confines of lyricism; but on occasion the legal system gets involved. An ongoing legal battle between one of the largest artists and largest record labels is the latest adventure of a rap battle turning legal. 

A diss track is a song targeted at a specific individual or group (usually another artist) that includes lyrics meant to publicly attack or disrespect them. In 2024, Kendrick Lamar and Drake, two of the largest rap artists in the world, traded diss tracks, bringing in millions of views every day, and generating months of online discourse. While the musical back and forth ended in May 2024, the artists’ feud reached a new boiling point in January 2025 when Drake filed a civil lawsuit in federal court against Universal Music Group (UMG) — the record label that represents both Kendrick and Drake. The lawsuit raises interesting questions on First Amendment free speech and defamation stemming from song lyrics.

The Timeline

While the story of Kendrick and Drake’s contentious relationship can be traced back over a decade, this saga began with the release of “First Person Shooter,” a collaboration between Drake and J. Cole containing a verse that crowned Drake, J. Cole, and Kendrick the big three of rap. This sparked a response from Kendrick in a featured verse on Future’s album, where he dismissed the big three and declared “it’s just big me.” 

This began a multi-month back and forth, consisting of eight tracks, that escalated into personal callouts between the two artists. On May 4, 2024, Kendrick would release his final track of the back and forth, and the song at issue in the lawsuit, “Not Like Us.” The track contains lyrics insinuating Drake has had inappropriate relationships with minors, which lay at the center of his claim against UMG. This song would transcend the rap battle and enter the mainstream; topping the Billboard Hot 100, amassing over one billion streams, and earning Kendrick Grammys for “Record Of The Year,” “Best Rap Performance,” “Best Rap Song,” and “Best Music Video.” Eight months after the release of Not Like Us, Drake would file his lawsuit against UMG.

The Lawsuit

Drake is clear in his complaint that this is not a lawsuit against Kendrick Lamar. Rather, the lawsuit has been filed against UMG, one of the largest record labels in the world. The lawsuit filed by Drake — whose legal name is Aubrey Graham — claims that the label has defamed him by promoting the song “Not Like Us”, which, as mentioned, insinuates Drake had inappropriate relationships. It is further alleged that UMG has artificially inflated streams through botting to boost the perceived success of the song. Drake believes the combination promotion and inflated popularity has directly led to threats and harassment, all of which have led to Drake suffering reputational harm, while the record label profited from the success of Kendrick’s song. Drake filed this lawsuit one month before Kendrick Lamar would perform “Not Like Us” to a live audience of over 130 million at the Super Bowl halftime show. In response, an amended complaint to claim that Kendrick’s performance and Grammy success further damaged his reputation. 

The Defamation Claim

Does Drake’s claim hold any weight? The answer isn’t crystal clear. 

To succeed on a typical defamation claim a plaintiff must establish four elements

  1. A false statement is made that is presented to be fact; 
  2. The statement is published or communicated to a third party;
  3. Defendant’s fault in releasing the statement amounts to at least negligence; and 
  4. Some reputational harm occurred to the person targeted by the statements. 

Here, Drake will have to establish an additional element. In the Supreme Court’s landmark New York Times v. Sullivan opinion, the Court established a legal doctrine that requires a plaintiff to prove actual malice when they are a public figure (someone who has achieved prominence and/or influence in society’s affairs). Establishing actual malice requires a heightened “clear and convincing” evidentiary standard; a middle ground between the civil “preponderance” standard and criminal “beyond a reasonable doubt” standard. 

Drake is undeniably a public figure. To show actual malice he must prove that UMG promoted Not Like Us with “reckless disregard of whether [the statement] was false or not.” Given this heightened standard, proving a defamation claim as a public figure is substantially more difficult than for an average citizen.  

UMG filed a motion to dismiss which raised the “rhetorical hyperbole” defense. Rhetorical hyperbole refers to exaggerated statements that a reasonable person would not take literally. This is an interesting legal doctrine in the context of rap battles. After all, the objective is to one-up each other’s lyrical call-outs until one artist is declared the “winner” through public opinion. It’s not as if “Not Like Us” came out of nowhere. Drake was an active participant in this back-and-forth. His own lyrics made claims that Kendrick was unfaithful and physically abusive to his partner. 

This would not be the first time UMG has raised a successful rhetorical hyperbole defense. In 2005, record producer Armen Boladian sued UMG about a verse performed by George Clinton containing  lyrics that painted Boladian as an abuser. The lyrics referred to him as “a disgrace to the species.” The Sixth Circuit Court of Appeals held that Boladian “failed to meet their burden of showing an actual, objectively verifiable defamatory statement”. The court noted the colorful lyrics to be the “kind of puerile taunt that, for better or worse, is typical of rap music.” Do Kendrick’s lyrics fall within this typicality of rap music? This will be a central question as litigation continues.

Conclusion

Is this a case of “be careful what you wish for?” Or has Kendrick overstepped the traditional protections afforded to musical works by courts and into defamation territory? Either way the legal battle for Drake appears to be an uphill one. Concerns about the potential chilling effect that artists may face if Drake were to win have also been raised. If litigation becomes the primary response to any perceived notion of defamation, a natural consequence of this would be the stifling of artistic expression as artists attempt to avoid liability that they previously felt insulated from. Whatever the end result, what started as a rap battle for the ages will be discussed and read about by law students in their entertainment law course for decades to come.

#WJLTA #DrakevsKendrick #Defamation 

Hitting Refresh: How Drug Companies Use Patents to Extend Their Monopoly Power

By: Alexander Okun

  On April 17, 2025, the non-profit Initiative for Medicines, Access, and Knowledge (“I-MAK”) published a report detailing the tactics that two pharmaceutical companies use to maintain their monopolies for their popular diabetes and obesity drugs. The two drugs are Semaglutide (marketed by Novo Nordisk as Ozempic, Rybelsus, and Wegovy) and Tirzepatide (marketed by Eli Lilly as Mounjaro and Zepbound). According to I-MAK, Novo Nordisk and Eli Lilly will effectively extend their patent-based monopolies on these drugs for up to a decade. The tactic of  “patent thickets” is not new to the pharmaceutical industry, but its potential economic impact as applied to these products (known collectively as “GLP-1” drugs) could be on a scale previously unseen. Given the adverse impact this could have on US patients, the need for legal reform is greater than ever.

“Patent Thickets” and Their Uses

A US pharmaceutical patent provides 20 years of protection, after which other manufacturers can produce generic versions of the drug. However, drug companies often file an array of patents for aspects beyond the drug’s core ingredients (called a “patent thicket”) like the method of administration. Subsequent changes to the product may also get patented (known as “secondary” or “follow-on” patents) but can be as minor as adding a dose counter to the injection device. Follow-on patents can also protect purportedly “new” applications of a drug without making any changes, even though those “novel” uses were  disclosed in the initial patent. For example, Eli Lilly’s Mounjaro is approved to treat diabetes while Zepbound is approved for weight loss even though Tirzepatide’s original patent disclosed both uses.

This practice is neither novel nor unique to the GLP-1 market: a 2018 report by I-MAK found that in 2017, the top 12 grossing medications in the US had an average of 71 active patents each, extending each drug’s protection for an average of 18 years. However, the profitability of those extensions is miniscule relative to the potential with GLP-1 drugs. Whereas the top-selling drug in I-MAK’s 2018 report, Humira, produced roughly $200 billion in revenue in its first 20 years, the GLP-1 market is projected to reach $150 billion in annual revenue by 2030. Novo Nordisk has already extended its patents for Ozempic and Wegovy by five years (expiring in 2031), which I-MAK says will deliver $166 billion in additional profits. As of now, patent thickets have effectively extended the protections for Semaglutide by 10 years (expiring in 2042) and Tirzepatide by five years (expiring in 2041). 

Potential for Reform

High drug prices are a perennial issue in US politics, and two proposals appear most promising in preventing further abuses of the patent system. The first approach is to limit the number of patents that can be cited in an infringement lawsuit. This would reduce the deterrent value of patent thickets by limiting the complexity of infringement actions (therefore defendants’ costs) and reducing plaintiffs’ likelihood of succeeding. The Affordable Prescriptions For Americans Act would implement this strategy, and on April 10 it was placed on the Senate’s legislative calendar. However, some analysts say the bill’s exemptions and waivers could make it largely ineffective.

A second option is to crack down on petitions that delay the approval of generic drug versions by using the filer’s patent thickets. The “Stop STALLING Act,” would enable the Federal Trade Commission (“FTC”) to sue filers if it deems a petition “objectively baseless” and intended to “interfere with the business of a competitor.”  However, the requirement of government intervention creates greater administrative costs and potential inconsistencies in enforcement. On April 10 the Stop STALLING Act was also placed on the Senate’s legislative calendar. While both bills have potential and bipartisan sponsorship, they have failed to garner sufficient support in their past iterations. Last year the Affordable Prescriptions for Patients Act passed the Senate unanimously but was never scheduled for a vote in the House of Representatives; the Stop STALLING Act never received a vote in the Senate whatsoever. Hopefully, the resounding success of GLP-1 drugs despite their exorbitant pricing will trigger public interest broad enough to provoke Congressional action.

Puff or Pass? Supreme Court Sides With FDA in Ruling on Flavored Vapes

By: Olivia Bravo

On April 2, 2025, the Supreme Court issued a ruling that reaffirmed the Food and Drug Administration’s authority to regulate flavored e-cigarettes, denying a challenge brought by vape manufacturers. This decision is a significant landmark for administrative law and public health advocates. Why was this decision so controversial? And what does it tell us about how courts balance corporate interests with public well-being?

Background

The Food and Drug Administration (FDA) is the administrative agency responsible for overseeing the introduction of new food and drug products into interstate commerce. Before approving new products to be marketed to the general public, the FDA requires manufacturers to submit premarket applications with  “robust” scientific data for review, demonstrating that their products are “appropriate for the protection of public health.” The FDA has the specific authority to regulate the manufacture, distribution, and marketing of tobacco products under the 2009 Family Smoking Prevention and Tobacco Control Act (Tobacco Control Act). In 2016, the Tobacco Control Act was amended under the Obama Administration to include e-cigarettes as products subject to agency review. 

Like many federal agencies, the FDA must act in accordance with the Administrative Procedure Act of 1946 (APA), which defines the limits of its regulatory authority and outlines the procedures it must follow when creating or enforcing rules. The APA, mandates transparency, consistency, and fairness in agency actions. That legal framework became central to the industry’s challenge. (See APA, 5 U.S.C. § 553). 

The Legal Challenge: FDA v. Wages and White Lion Investments, LLC

In the precursor Fifth Circuit case FDA v. Wages and White Lion Investments, LLC, plaintiffs White Lion and other manufacturers of e-cigarettes submitted to the FDA applications to market their flavored tobacco products – but were rejected for lacking long-term studies demonstrating health benefits and marketing plans that met regulatory standards. 

The companies pushed back hard, arguing that the FDA had applied inconsistent and opaque standards, effectively moving the goalposts without notice. They claimed that flavored vapes were unfairly singled out and that the FDA’s review process was arbitrary, violating the APA. They contended that this created an uneven playing field, treating flavored e-cigarettes more harshly than other tobacco products and leaving applicants to guess at the “robust standards” they needed to meet. The Fifth Circuit ultimately agreed, holding that the FDA acted outside the scope of its authority. The case was then appealed to the Supreme Court, which granted cert.

FDA Denial and Industry Pushback

What is the crux of the matter? Why did the FDA  deny the companies’ applications to sell their e-cigarettes? 

E-cigarettes and vapes are only two of the many electronic delivery system (ENDS) products that use an “e-liquid” nicotine derived from tobacco (as well as flavorings) as an aerosol that is inhaled. In this case, White Lion’s rejected products included flavors like Killer Kustard Blueberry, Rainbow Road, and Pineapple Express, sold in brightly colored packaging resembling candy or cartoons. The FDA argued that this targeted marketing posed a significant risk to youth. In the last decade, the United States has seen an explosive rise in adolescents’ vaping and the renormalization of smoking, especially among high schoolers. In 2024, 1.63 million middle and high school students used e-cigarettes. Recent statistics show that flavor is one of the most important factors adolescents consider when trying e-cigarettes for the first time. 

The vaping industry continues to frame flavored e-cigarettes as a public health innovation—a tool for adult users seeking an alternative to traditional cigarettes. Companies like Triton and Vapetasia claim their flavored vapes provide a public good by helping adult smokers quit cigarettes, with flavors making it more likely that adult smokers will transition away from combustible tobacco. However, the FDA found that e-cigarettes pose a “known and substantial” risk to youth, and concluded that the risks of bringing a new product to market outweighed any potential benefit. 

Supreme Court Review: Reversing the Fifth Circuit

Earlier this month, in the unanimous Supreme Court decision, Justice Alito agreed with the FDA that the flavored e-cigarettes and vapes proved a danger to the health of young people, writing “the kaleidoscope of flavor options adds to the allure of e-cigarettes and has thus contributed to the booming demand for such products among young Americans.” The Court found that the FDA’s actions did not violate the APA and were consistent with its regulatory responsibilities

The Supreme Court and the Fifth Circuit’s decisions differed based on their standards of procedural adherence. While the Fifth Circuit applied a stringent standard, arguing that the FDA acted arbitrarily and capriciously by shifting its standards, the Supreme Court deferred to the FDA’s expertise when no formal policy changes were in place, arguing that their decisions were not outside the scope of their authority. This divergence highlights the broader tension between judicial oversight of agency action and deference to agency expertise in complex regulatory matters, especially those that will have long-term effects on public health.

Conclusion

The Supreme Court’s decision affirms the FDA’s authority to prioritize public health and interstate commerce. In terms of implications for the vaping industry, it is clear the court has drawn the line in the sand between commercial interest and public health priorities, and set a standard for the prioritization of the youth impact over the harm to adult cigarette smokers. While this Court might have previously made different decisions concerning federal agency regulation, it is clear that the targeted health risk to youth was enough of a concern to find in favor of the FDA, whereas in another case, the Court might have gone the other direction.  

Overall, the controversy in this case was a big wake-up call for the FDA and all regulatory agencies that set guidelines for growing and advancing industries. While it might have been easier to set standards for cigarettes when the harmful effects of lung cancer were widely known, the technological and marketing advances of e-cigarettes and other alternative tobacco products have made it difficult for the FDA to keep up with both the pace of innovation and the health implications. Why leave the question of clear regulatory standards and guidelines up for interpretation? Change requirements to keep pace with the advancing world and give notice of those changes in line with transparency.  

#E-cigarettes #FDA #Regulatoryauthority #WJLTA

Reassessing In-Game IP Use: Lessons from AM General LLC v. Activision Blizzard, Inc.

By: Miranda Glisson

            Recently, I’ve developed a growing interest in car racing – particularly open-wheel, sports car, and touring car disciplines. As a result, I entered the world of Forza video games, including Forza Horizon and Forza Motorsport. While I practiced my driving skills in a not-too-fancy simulator playing Forza Motorsport, I wondered about the challenges Forza and other video games must face with licensing trademarked subject matter like cars after the AM General LLC v. Activision Blizzard, Inc. decision. 

IP Licensing in Video Games

Video games represent the pinnacle of interactive intellectual property, often requiring developers and producers to secure numerous licenses for a single game. Video game licensing refers to an agreement between a video game producer and an external company granting the producer permission to use the company’s intellectual property in their game. Game producers may employ licenses to use copyrighted and trademarked works in their games.

            Video game producers and external companies negotiate and agree upon each license.  Each license can have differing stipulations depending on how an external company wants their copyrighted or trademarked logo/work used within the game, ensuring the user’s perception of the external company’s work aligns with that company’s desire in how they are perceived.

Video game developers may want to obtain permission to use a third party’s trademark in their game to bring their creative vision to life. Incorporating trademarks from other companies can enhance realism, enable parody, or support commentary. However, obtaining the permission to use a trademark in a video game varies in difficulty, and the licenses can boast specific terms and conditions regarding use, scope, duration, quality control, and fees.

AM General LLC v. Activision Blizzard, Inc.

Trademark licenses may not be required when video game developers use the trademarked subject matter artistically or expressively. When one’s trademark is used in an artistic or expressive way by another, courts have narrowly interpreted the Lanham Act (the primary federal statute governing trademark law in the United States) to avoid suppressing protected speech under the First Amendment. In AM General LLC v. Activision Blizzard, Inc., AM General brought a trademark infringement claim against Activision Blizzard for using Humvees in their game, Call of Duty, without obtaining permission. The court determined the inclusion of Humvees in the game was intended to enhance realism, deeming their use as an expressive form of creativity. As a result, Activision Blizzard was within its rights to incorporate real-world subjects for artistic purposes and thus did not infringe upon AM General’s trademark.

AM General LLC v. Activision Blizzard, Inc. had significant impacts on video game licensing by establishing that real-world objects that are depicted in video games enhance artistic realism are protected under the First Amendment. As a result, video game developers do not need to obtain a license from trademark holders if the use is to enhance artistic realism. However, it is unclear how far the holding of AM General LLC v. Activision Blizzard, Inc. reaches. A major factor in the AM General LLC v. Activision Blizzard, Inc. decision was that consumer confusion was unlikely between the plaintiff’s Humvees and the defendant’s game, as there was no evidence of significant market overlap or direct competition. Accordingly, it would be expected that if there was market or consumer overlap between one party’s work and the other’s trademark, there would not be protected use of that mark, and therefore, a license would be required.

            I, as a very novice video game player, enjoy video games’ depictions of realism as it enhances immersion. As video games incorporate brands and products into their games to enhance realism, developers are required to navigate when trademark licensing agreements are required or not. Decisions like AM General LLC v. Activision Blizzard, Inc. show that trademarks can be used if they are for artistic or expressive purposes, if there is little likelihood of consumer confusion. However, this boundary is uncertain and likely creates difficulty for video game developers as, ultimately, video games are a mix of art, collaboration, and commerce, creating difficult intellectual property challenges.

#videogames #artisticrealism #trademarks

Diarra v. FIFA: A Clash Between Global Sports Governance and Individual Labor Rights

By: Tavis McClain

When a footballer challenges the most powerful governing body in sports, the world pays attention. Lassana Diarra, a talented midfielder, has entered into a stand-off with the very institution meant to uphold the spirit of the game. This case incited intense debate on fairness, freedom, and the balance of power in professional football.

Introduction

Diarra v. FIFA challenges the foundational structures of sports governance. This dispute raises crucial questions about how international sports bodies govern, how athletes assert their rights, and where the boundaries lie between sporting rules and fundamental labor protections. The situation is emblematic of a deeper tension in modern sport: the power of centralized global institutions like FIFA versus the rights of individuals navigating the professional system. It reveals a crucial lens into how the governance of international sport must adapt in response to legal, ethical, and human rights standards.

Background

Lassana Diarra, a well-regarded French international, terminated his contract with Russian club Lokomotiv Moscow in 2014. Diarra claimed the club had breached the contract by failing to pay his wages and creating a hostile work environment. However, FIFA’s Dispute Resolution Chamber (DRC) ruled Diarra had no just cause for the termination as there wasn’t sufficient evidence of a breach by Lokomotiv Moscow. FIFA subsequently imposed a fine and a global playing ban until the compensation was paid—a punishment that effectively paused Diarra’s career and forced him out of the game.

FIFA’s Ruling and CAS Appeal

Diarra appealed to the Court of Arbitration for Sport (CAS), which largely upheld FIFA’s decision. Decisions from the CAS are generally considered binding on FIFA as well as other institutions. The CAS ruling emphasized the principle of contractual stability in football—a cornerstone of FIFA’s regulations, designed to prevent players and clubs from breaching agreements unilaterally. Diarra subsequently challenged the ban in French civil courts, arguing that the enforcement of FIFA’s decision within national jurisdiction violated his fundamental labor rights, particularly his right to work.

Global Sports Governance Under Scrutiny

FIFA, as the global governing body of football, enforces a centralized dispute resolution system designed to streamline legal matters and preserve uniformity across jurisdictions. This case, however, exposes the limitations of that model:

  • Enforcement Without Borders: FIFA’s global ban extended beyond Russia, restricting Diarra’s ability to play in any league worldwide. This reveals how sports governing bodies can bypass national labor protections through international enforcement.
  • Lack of Worker Protections: FIFA’s mechanisms often prioritize contractual order over employee rights, a model that may not always align with domestic labor standards, especially within the EU.
  • Limited Transparency and Appeal: The CAS arbitration system, while designed for expediency, is often criticized for its lack of transparency, limited recourse, and the asymmetry in power between athletes and governing bodies.

What This Means for Labor Rights in Sport

  1. The Right to Just Cause
    The case demonstrates how difficult it can be for players to assert just cause in contract disputes, especially when proving workplace mistreatment or unpaid wages. It sparks questions about the fairness of a system where players are held to stricter standards than employers. Players are forced to prove they were not fired for a legitimate purpose, while FIFA is not required to present evidence.
  2. Access to National Legal Systems
    Diarra’s recourse to the French courts signaled that national jurisdictions can and will challenge the authority of sports bodies when fundamental rights are at stake. This could set a precedent for athletes bypassing arbitration if labor rights are seen to be compromised. If FIFA does not provide relief when its players have their labor rights violated, then they will seek alternative routes of action. It is in the interest of FIFA and the players to settle these conflicts on their behalf to reduce transaction costs and promote transparency.
  3. Rethinking the Role of CAS
    As the de facto “supreme court” of sports, CAS must adapt its structure to better balance institutional interests with individual protections. The current structure favors institutional interests over those of the individual. This may include more transparent hearings, greater independence, and recognition of fundamental labor norms. If these changes are made, it may remedy the issues that footballers are facing.

Conclusion

Diarra v. FIFA exposed a fault line between the old world of insular sports governance and the new reality where labor rights and ethical governance matter more than ever. For international sport to remain credible and fair, its legal infrastructure must shift toward transparency, equity, and respect for the individual.